Reuters logo
BRIEF-Redhill Biopharma provides 2017 semi-annual business update
January 12, 2017 / 11:18 AM / a year ago

BRIEF-Redhill Biopharma provides 2017 semi-annual business update

Jan 12 (Reuters) - Redhill Biopharma Ltd

* Provides 2017 semi-annual business update

* Re-submission of Rizaport NDA to FDA is expected in first half of 2017

* Top-line results are expected in mid-2017 from clinical study with Bekinda Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below